LGD-4033 (Ligandrol) is a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (RA) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 (Ligandrol) is expected to produce the therapeutic benefits of …